血清糖链抗原125和人附睾分泌蛋白4联合检测在卵巢癌诊断中的价值

目的探讨糖链抗原125(CA125)和血清人附睾分泌蛋白4(HE4)联合检测在卵巢癌诊断中的价值。方法检测82例女性血清CA125和HE4水平,其中26例健康女性为正常对照组,56例卵巢肿瘤患者按术后病理结果分为良性病变组30例和卵巢癌组26例,分析和比较肿瘤标志物在不同组别血清中的表达水平,以及各组单项指标和联合检测的阳性率。结果卵巢癌组CA125和HE4水平明显高于良性病变组和正常对照组(P<0.05),且晚期卵巢癌CA125和HE4水平明显高于早期卵巢癌(P<0.05)。CA125和HE4单项检测卵巢癌阳性率分别为50.00%(13/26)和53.85%(14/26),联合检测的阳性率为73.08%(19/26),明显高于单项检测CA125和HE4的阳性率,差异均有统计学意义(P<0.05)。结论 CA125和HE4联合检测有助于提高卵巢癌的检出率。

Diagnostic value of combined determination of serum carbohydrate antigen 125 and human epididymis secretory protein 4 in patients with ovarian cancer

Objective To investigate the diagnostic value of combined determination of serum carbohydrate antigen 125(CA125) and human epididymis secretory protein 4(HE4) in patients with ovarian cancer.Methods Serum CA125 and HE4 levels were determined in 82 cases including 26 cases of normal control group,30 cases of benign ovarian disease group and 26 cases of ovarian cancer group.The levels of CA125 and HE4 in different groups were analyzed and compared,the positive rate of single CA125,single HE4 and the combined determination of CA125 and HE4 were compared.Results The levels of CA125 and HE4 were significantly higher in ovarian cancer group than those in benign ovarian disease group and normal control group(P<0.05),and the levels of CA125 and HE4 in advanced ovarian cancer were significantly higher than those in early ovarian cancer(P<0.05).The positive rate of CA125 and HE4 was 50.00%(13/26) and 53.85%(14/26) respectively.The positive rate of combined determination was 73.08%(19/26).The positive rate of combined determination was significantly higher than that of single CA125 or HE4(P<0.05).Conclusion The combined determination of CA125 and HE4 can improve the positive rate of ovarian cancer.